SELLAS Life Sciences Group (SLS) EBIAT: 2011-2023
Historic EBIAT for SELLAS Life Sciences Group (SLS) over the last 4 years, with Dec 2023 value amounting to -$8.1 million.
- SELLAS Life Sciences Group's EBIAT rose 10.80% to -$8.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.3 million, marking a year-over-year increase of 9.58%. This contributed to the annual value of -$37.3 million for FY2023, which is 9.59% up from last year.
- As of Q4 2023, SELLAS Life Sciences Group's EBIAT stood at -$8.1 million, which was up 12.20% from -$9.3 million recorded in Q3 2023.
- SELLAS Life Sciences Group's 5-year EBIAT high stood at -$2.4 million for Q1 2021, and its period low was -$16.7 million during Q1 2022.
- For the 3-year period, SELLAS Life Sciences Group's EBIAT averaged around -$8.3 million, with its median value being -$8.3 million (2022).
- Per our database at Business Quant, SELLAS Life Sciences Group's EBIAT skyrocketed by 42.00% in 2021 and then tumbled by 596.80% in 2022.
- SELLAS Life Sciences Group's EBIAT (Quarterly) stood at -$3.7 million in 2020, then crashed by 77.56% to -$6.6 million in 2021, then crashed by 38.24% to -$9.1 million in 2022, then rose by 10.80% to -$8.1 million in 2023.
- Its EBIAT stands at -$8.1 million for Q4 2023, versus -$9.3 million for Q3 2023 and -$8.8 million for Q2 2023.